Defining Progression in Metastatic Kidney Cancer

3 Views
administrator
administrator
06/26/23

Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next